Rene C. Gonzalez
Impact in
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Colorectal Cancer Treatments and Studies
- Immunology top 0.05%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 98
- Cutaneous Melanoma Detection and Management 38
- CAR-T cell therapy research 33
- Cancer Immunotherapy and Biomarkers 32
- Colorectal Cancer Treatments and Studies 6
- Immunology 39
- Immunotherapy and Immune Responses 30
- Co-authors
- Karl D. Lewis (49 shared papers)William Allen Robinson (40 shared papers)Dirk Schadendorf (11 shared papers)Frank Stephen Hodi (15 shared papers)Martin D. McCarter (23 shared papers)Steven J O'Day (17 shared papers)Piotr Lukasz Rutkowski (7 shared papers)Christopher D. Lao (8 shared papers)
- Journals
- Journal of Clinical Oncology (19 papers)Melanoma Research (12 papers)Annals of Oncology (12 papers)New England Journal of Medicine (9 papers)Clinical Cancer Research (7 papers)
- Partner nations
- United StatesAustraliaFrance
In The Last Decade
Rene C. Gonzalez
196 papers receiving 48.0k citations
Rene C. Gonzalez's Hit Papers
Peers
Comparison fields: 5 of 161
- Oncology 32.7k
- Immunology 15.1k
- Molecular Biology 16.0k
- Cancer Research 2.9k
- Pulmonary and Respiratory Medicine 4.8k
Countries citing papers authored by Rene C. Gonzalez
This map shows the geographic impact of Rene C. Gonzalez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rene C. Gonzalez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rene C. Gonzalez more than expected).
Fields of papers citing papers by Rene C. Gonzalez
This network shows the impact of papers produced by Rene C. Gonzalez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rene C. Gonzalez. The network helps show where Rene C. Gonzalez may publish in the future.
Co-authors
The 25 scholars most cited alongside Rene C. Gonzalez, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 196 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma Hit paper breakdown → | 2010 | 12635 |
| 2 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma Hit paper breakdown → | 2015 | 6916 |
| 3 | Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2017 | 4597 |
| 4 | Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2019 | 2848 |
| 5 | Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations Hit paper breakdown → | 2012 | 2337 |
| 6 | Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib Hit paper breakdown → | 2012 | 1823 |
| 7 | Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma Hit paper breakdown → | 2017 | 1783 |
| 8 | Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial Hit paper breakdown → | 2015 | 1348 |
| 9 | Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial Hit paper breakdown → | 2018 | 1153 |
| 10 | RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors Hit paper breakdown → | 2012 | 889 |
| 11 | gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma Hit paper breakdown → | 2011 | 730 |
| 12 | Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma Hit paper breakdown → | 2009 | 517 |
| 13 | Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma Hit paper breakdown → | 2022 | 492 |
| 14 | Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin Hit paper breakdown → | 2013 | 491 |
| 15 | Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma Hit paper breakdown → | 2009 | 465 |
| 16 | 2012 | 459 | |
| 17 | 2012 | 405 | |
| 18 | 2017 | 365 | |
| 19 | 2013 | 311 | |
| 20 | 2019 | 310 |
About Rene C. Gonzalez
Rene C. Gonzalez is a scholar working on Oncology, Immunology, Molecular Biology, Radiology, Nuclear Medicine and Imaging and Immunology and Allergy, having authored 196 papers that have together received 49.2k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (53 papers), Cutaneous Melanoma Detection and Management (38 papers), CAR-T cell therapy research (33 papers), Cancer Immunotherapy and Biomarkers (32 papers), Immunotherapy and Immune Responses (30 papers), Monoclonal and Polyclonal Antibodies Research (15 papers), Cell Adhesion Molecules Research (8 papers) and Colorectal Cancer Treatments and Studies (6 papers). The work is most often cited by research in Oncology (32.7k citations), Immunology (15.1k citations), Molecular Biology (16.0k citations), Cancer Research (2.9k citations) and Pulmonary and Respiratory Medicine (4.8k citations). Rene C. Gonzalez has collaborated with scholars based in United States, Australia and France. Frequent co-authors include Karl D. Lewis, William Allen Robinson, Dirk Schadendorf, Frank Stephen Hodi, Martin D. McCarter, Steven J O'Day, Piotr Lukasz Rutkowski, Christopher D. Lao, Jedd D. Wolchok and David Hogg. Their work appears in journals such as Journal of Clinical Oncology, Melanoma Research, Annals of Oncology, New England Journal of Medicine and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.